DVA News and Press, DaVita Inc. From 10/18/23

DaVita Collaborates with Google Cloud to Develop Customized Clinical Operating System Designed to Transform Kidney Care PR Newswire Kidney care provider harnesses the power of Google Cloud's leading-edge infrastructure, AI, and analytics tools to help improve care plans and st...

DaVita Inc. Schedules 3rd Quarter 2023 Investor Conference Call PR Newswire DENVER , Oct. 17, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, Nove...

2023-10-17 15:23:07 ET Summary Healthcare providers are undervalued by about 9% relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on iShares U.S. Healthcare Providers ETF, a healthcare providers fund. 10 stocks cheaper than the...

2023-10-13 08:00:00 ET Summary Investors are pulling out of the stock market and into lower-yielding investments like T-bills, causing stock prices to drop. REITs, such as Agree Realty and Realty Income, have seen their prices decline, presenting an opportunity for investors. ...

2023-10-12 15:39:22 ET More on Fresenius Medical Care Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2023 Earnings Call Transcript Fresenius Medical Care: Heads Don't Roll - They Run ...

2023-10-12 13:24:12 ET More on Baxter, DaVita, etc. Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial? Outset Medical Faces Regulatory Delays Amid Heavy Cash Burn (Rating Downgrade) DaVita: Continued Economic Hurdles, Market Expectations May Be...

2023-10-12 10:54:14 ET Summary Novo Nordisk ended its kidney outcome trial early after interim results showed the efficacy of its drug-Ozempic in delaying the progression of chronic kidney disease. Stocks of medical equipment major, Baxter International, and kidney care servicing ...

DaVita Statement on GLP-1 and Potential Implications on Chronic Kidney Disease PR Newswire DENVER , Oct. 12, 2023 /PRNewswire/ -- DaVita issued the following statement in response to news this week from Novo Nordisk, manufacturer of Ozempic®, a glucagon-like...

2023-10-11 14:51:11 ET More on DaVita DaVita: Continued Economic Hurdles, Market Expectations May Be Correct DaVita stock sell-off over Ozempic study 'big overreaction,' says UBS DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold ...

2023-10-11 12:51:59 ET Shares of several major dialysis stocks plunged on Wednesday after Novo Nordisk (NYSE: NVO) indicated one of its diabetes treatments could also be used to treat chronic kidney disease. Dialysis products and services providers were broadly negative in early...